{"id":"NCT02262260","sponsor":"Novartis Pharmaceuticals","briefTitle":"Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME","officialTitle":"A Randomized, Open-label Non-inferiority Study to Compare Safety and Efficacy of Labeled Versus Wait and Extend Regimen of Lucentis (Ranibizumab) in Turkish Patients With Visual Impairment Due to Diabetic Macular Edema.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12-12","primaryCompletion":"2017-09-12","completion":"2017-09-12","firstPosted":"2014-10-13","resultsPosted":"2019-06-24","lastUpdate":"2019-06-24"},"enrollment":87,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Macular Edema"],"interventions":[{"type":"DRUG","name":"Labeled regime arm","otherNames":["Arm 1"]},{"type":"DRUG","name":"Wait and Extend regime arm","otherNames":["Arm 2"]}],"arms":[{"label":"Ranibizumab labeled regime arm","type":"EXPERIMENTAL"},{"label":"Ranibizumab wait and Extend regime arm","type":"EXPERIMENTAL"}],"summary":"To explore a more clinical feasible treatment regime with ranibizumab for DME to provide satisfactory treatment effect with a lower number of visits and injections.","primaryOutcome":{"measure":"Mean Change in \"Best-corrected Visual Acuity\" at Month 12","timeFrame":"12 months","effectByArm":[{"arm":"Labeled Regime Arm","deltaMin":76.44,"sd":1.78},{"arm":"Wait and Extend Regime Arm","deltaMin":73.09,"sd":1.68}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":9,"countries":["Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":45},"commonTop":["Ocular hyperemia","Eye haemorrhage","Vitreoretinal traction syndrome","Abdominal pain upper","Diarrhea"]}}